ESMO TAT 2023 | eNRGy: zenocutuzumab in NRG1 fusion–positive tumors

Alison Schram, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses findings from Phase II eNRGy trial (NCT02912949) of zenocutuzumab, a novel bispecific antibody targeting both HER2 and HER3, in patients with NRG1 fusion–positive tumors. Zenocutuzumab was well tolerated and promising activity was reported, especially in patients with pancreatic and non-small cell lung cancer. The investigational therapy represents a potential treatment option for a group of patients with no current approved therapies.

This interview took place at the ESMO Targeted Anticancer Therapies (TAT) Congress 2023 in Paris, France.